Clinical Research Studies

Study: Efficacy and Safety study of RPT193 as Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis

Purpose: This study is being done to evaluate the safety and tolerability of RPT193 in subjects with moderate to severe atopic dermatitis, also known as eczema. Investigational product will be administered as monotherapy for AD in adult patients who have had an inadequate response to topical medications for AD (e.g., corticosteroids) or who are otherwise unable to take topical medications.

Qualifications:

• Male and Females, 18 to 75 years old
• Clinical diagnosis of Atopic Dermatitis
• Documented history of inadequate response to a ≥1 month treatment with topical medications

Duration: Up to 7 months
Locations: Hackensack, NJ
Principal Investigator: Dr. David Goldberg
Compensation: Up to $650

Interested in participating in our clinical research study? Please click here.

---

Study: Phase 2 study to evaluate the efficacy and safety of RPT193 as monotherapy in adults with moderate-to severe atopic dermatitis (oral tablet)

Purpose: This study is being conducted to evaluate the clinical efficacy, safety and tolerability of RPT193 following oral multiple-dose, administration once a day, for 16 weeks to participants with moderate-to-severe Atopic Dermatitis. Atopic dermatitis is commonly known as eczema. The investigational product is given as a monotherapy for AD in adult participants who have had an inadequate response to topical medications given to them for AD or who are otherwise unable to use topical medications.

Qualifications:

• Adults age 18-75 years with a clinically confirmed diagnosis of AD
• At least a 12 month history of AD with no significant flares in AD for at least 4 weeks before Screening
• Documented history of inadequate response to a >1 month treatment with topical medication for AD (e.g. corticosteroids) or unable to use topical medications

Duration: Up to 7 months with about 10 visits
Locations: Verona, NJ
Principal Investigator: Robert Nossa, M.D.
Compensation: $80 per completed site visit
Click here to view Q&A

Inquires can be sent to malgorzata.lopez@schweigerderm.com Interested in participating in our clinical research study? Please click here.

---

Study: Psoriasis of the Nails with moderate to severe plaque psoriasis on the body: Evaluating an FDA approved medication

Purpose: PCD, a division of Schweiger Dermatology Group, is currently enrolling subjects in Exton in a clinical trial for the treatment of Psoriasis of the Nails with Psoriasis elsewhere on the body. The trial is evaluating an FDA approved medication.

Qualifications:

• Male or Female adult subjects, age ≥ 18 years of age
• Nail Psoriasis must be present on at least one nail

Length of study: 52 weeks. Subjects seen 5 times in 52-week period
Locations: 501 Gordon Drive, Exton, PA 19341
Principal Investigator: Scott Gottlieb, M.D.
Compensation: Up to $350
Contact Bobbi Roth at Roberta.Roth@schweigerderm.com and Abby Patrizio at Abigail.Patrizio@schweigerderm.com

Interested in participating in our clinical research study? Please click here.

---

Study: Scalp Psoriasis with Psoriasis on the body in subjects who are non-white: Evaluating an FDA approved medication

Purpose: PCD, a division of Schweiger Dermatology Group, is currently enrolling subjects in Exton in a clinical trial for the treatment of predominantly Scalp Psoriasis with Psoriasis on the body in Subjects who are non-white. The trial is evaluating an FDA approved medication.

Qualifications:

• Male or Female adult subjects, age ≥ 18 years of age
• Be Non-White, as per self-reported race/ethnicity
• Have moderate to severe scalp psoriasis with some psoriasis elsewhere on the body

Length of study: 112 weeks. Subjects seen 20 times in 112-week period
Locations: 501 Gordon Drive, Exton, PA 19341
Principal Investigator: Scott Gottlieb, M.D.
Compensation: Up to $1040
Contact Bobbi Roth at Roberta.Roth@schweigerderm.com and Abby Patrizio at Abigail.Patrizio@schweigerderm.com

Interested in participating in our clinical research study? Please click here.

---

Study: Treatment of moderate to severe Atopic Dermatitis (Eczema)

Purpose: PCD, a division of Schweiger Dermatology Group, is currently enrolling subjects in Exton in a clinical trial for the treatment of moderate to severe Atopic Dermatitis (Eczema).

Qualifications:

• Male or Female subjects, age ≥ 6 months
• Have moderate to severe atopic dermatitis (eczema)

Length of study: 16 weeks plus long-term extension study. Subjects seen 12 times in 16-week period
Locations: 501 Gordon Drive, Exton, PA 19341
Principal Investigator: Scott Gottlieb, M.D.
Compensation: Up to $675
Contact Bobbi Roth at Roberta.Roth@schweigerderm.com and Abby Patrizio at Abigail.Patrizio@schweigerderm.com

Interested in participating in our clinical research study? Please click here.

---

Study: Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Purpose: This study is being done to evaluate the safety and tolerability of Rocatinlimab (AMG 451) in subjects with moderate to severe atopic dermatitis, also known as eczema. Investigational product will be administered as monotherapy for AD in combination with topical corticosteroids/topical calcineurin inhibitor. This is a placebo-controlled, double-blind study.

Qualifications:

• Males and Females, ages 18 or older
• Clinical diagnosis of Atopic Dermatitis
• Documented history of inadequate response to topical corticosteroids within 6 months

Duration: Approximately 6 months
Locations: Hackensack, NJ
Principal Investigator: Dr. David Goldberg
Compensation: $30 per visit will be paid to the patient *once all visits are completed*

Interested in participating in our clinical research study? Please click here.

---

Study: Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects with Atopic Dermatitis

Purpose: This study is being done to evaluate to evaluate the efficacy of 2 dose levels of oral difelikefalin as adjunct therapy to a topical corticosteroid (TCS), compared to placebo and to TCS alone, in reducing the intensity of itch after 12 weeks of treatment for moderate-to-severe pruritus in adult subjects with atopic dermatitis (AD).

Qualifications:

• Males and Females, between 18 – 80 years of age
• Clinical diagnosis of active Atopic Dermatitis
• Chronic pruritus related to Atopic Dermatitis

Duration: Approximately 4 months
Locations: Hackensack, NJ
Principal Investigator: Dr. David Goldberg
Compensation: $68 per visit will be paid to the patient *once all visits are completed*

Interested in participating in our clinical research study? Please click here.

---

Study: Evaluation of Non-Treatment Mind.Px Patch for Plaque Psoriasis

Purpose: The purpose of this investigation is to evaluate the impact of Mind.Px on response to biologic treatment for Plaque Psoriasis. This is not meant to treat plaque psoriasis, but to inform the physician on the likelihood for a patient to respond to one or more biologic treatments.

Qualifications:

• Males and females, ages 18 or older
• Medical diagnosis of plaque psoriasis

Duration: Approximately 16 weeks
Locations: Hackensack, NJ
Principal Investigator: Dr. David Goldberg
Compensation: Up to $630

Interested in participating in our clinical research study? Please click here.

---

Study: Evaluation of Non-Invasive Applicator for Submental Subcutaneous Adipocyte Tissue

Purpose: The purpose of this investigation is to evaluate the BTL-785F system for the treatment of Submental Subcutaneous fat in adult subjects. The subjects will be enrolled into two study groups: Group A will receive active treatment and Group B will serve as the control. Both groups will receive 4 biopsies in the treatment area.

Qualifications:

• Males and females, ages 21 or older
• Clearly visible excess submental fat
• Must be available 24 hours, 7 days, and 14 days after treatment

Duration: Approximately 1 month
Locations: Hackensack, NJ
Principal Investigator: Dr. David Goldberg
Compensation: Up to $650

Interested in participating in our clinical research study? Please click here.

---